My ePortfolio Register   

Olaparib and temozolomide for relapsed small cell lung cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.04.17
Views: 1672

Dr Anna Farago - Massachusetts General Hospital, Boston, USA

Dr Farago speaks with ecancer at AACR 2017 about results from a phase I/II study of treating patients with small cell lung cancer (SCLC) following relapsed after chemotherapy.

She describes the rationale of adding olaparib, a PARP inhibitor preventing DNA repair, to temozolomide which induces single strand breaks, with a hopeful synergy for controllable cell death within tumours.

Dr Farago describes the doses in the trial as well tolerated, with a response rate of 48% and a median PFS of 5.6 months.

She also highlights the utility of patient derived xenografts to chart patient responses through time, and identify stages of resistance and response.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence